Article Text

Download PDFPDF
Intra-abdominal bleeding during treprostinil infusion in a patient with pulmonary arterial hypertension
  1. Stephanie Mindus1,
  2. Jacek Pawlowski2,
  3. Magnus Nisell1,
  4. Giovanni Ferrara1,3,4
  1. 1Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden
  2. 2Department of Radiology, Section of Thoracic Radiology, Karolinska University Hospital, Stockholm, Sweden
  3. 3Department of Medicine, Section of Respiratory Diseases, University of Perugia, Perugia, Italy
  4. 4Respiratory Medicine Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
  1. Correspondence to Dr Giovanni Ferrara, giovanni.ferrara{at}


Medical treatment of pulmonary arterial hypertension (PAH) is increasingly common. Prostacyclins were introduced in the early 90s, and treprostinil is one of the most frequently used drugs of this class today, owing to its long half-life and to the possibility to administer the molecule through several routes. Treprostinil is considered a safe drug and is associated with a significant improvement of exercise capacity, especially in patients with idiopathic PAH (iPAH). Systemic sclerosis-associated PAH (sc-PAH) correlates to a worse prognosis compared with that of iPAH. Despite these considerations, safety data on treprostinil are still limited and mainly derived from randomised controlled trials and retrospective studies with relatively small and heterogeneous cohorts of patients with PAH. We report the occurrence of a severe intra-abdominal bleeding during treprostinil infusion in a patient with sc-PAH.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.